Prostate Cancer Clinical Trials in Miami

Showing 141-158 of 158 trials

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

NCT00503984

Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.

Prostate CancerPain

University of Miami22 participantsStarted May 2007

Miami, Florida, United States

COMPLETEDPhase 3< 1 mile

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases. PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have bone metastases from breast or prostate cancer.

Breast CancerMetastatic CancerPain+1 more

Radiation Therapy Oncology Group949 participantsStarted Feb 1998

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +250 more locations

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Prostate Cancer Trials in Other Cities

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

A Trial of Degarelix in Patients With Prostate Cancer

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

Other Conditions in Miami